Co-Authors
This is a "connection" page, showing publications co-authored by CHRISTOPHER J LOGOTHETIS and PETER F THALL.
Connection Strength
0.882
-
Radiotherapy for metastatic prostate cancer. Lancet. 2019 09 07; 394(10201):829-830.
Score: 0.176
-
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30.
Score: 0.113
-
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med. 2007 Nov 20; 26(26):4687-702.
Score: 0.078
-
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2007 Nov 07; 99(21):1613-22.
Score: 0.077
-
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24.
Score: 0.077
-
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61.
Score: 0.072
-
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9.
Score: 0.062
-
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 01; 21(5):878-83.
Score: 0.056
-
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer. 2003 Feb 01; 97(3):561-7.
Score: 0.056
-
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002 Jul 15; 20(14):3072-80.
Score: 0.054
-
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
Score: 0.021
-
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008 Nov 04; 99(9):1426-32.
Score: 0.021
-
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate. 2007 Nov 01; 67(15):1677-85.
Score: 0.019